Related Experiment Video
Updated: Aug 7, 2026

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis (NASH) Resolution
Published on: April 16, 2019
A clinical and experimental investigation of liraglutide effects on the brain-kidney axis
Michael P Greenwood1,2, Mohammed I Alotaibi1,3, Soledad Bárez-López1,4
1Molecular Neuroendocrinology Research Group, Bristol Medical School: Translational Health Sciences, University of Bristol, Dorothy Hodgkin Building, Bristol, UK.
Abstract:
Glucagon-like peptide-1 receptor agonists elicit diuresis and natriuresis in humans and rodents. However, little is known about their interactions with the bodies hormonal systems that control fluid homeostasis. We performed a single center, open-label, before-and-after study and discovered that liraglutide reduces plasma arginine vasopressin (AVP) levels in healthy humans. By quantitative proteomic and phosphoproteomic investigation of the rat pituitary gland, we detail time- and sex-dependent modifications to synaptic proteins mediated by liraglutide. We developed an in vitro AVP luciferase assay to assess the impact of synaptic protein phosphorylation on AVP secretion. We used this assay to identify synaptic protein phosphosites that influence AVP release and liraglutide-mediated sex differences in AVP release. Investigation of AVP downstream signaling pathways in the kidney revealed posttranslational changes to the crucial AVP-regulated water channel aquaporin 2. Thus, glucagon-like peptide-1 receptor agonist modulation of AVP release may be responsible for cardiovascular and renal changes observed in patients.
Related Concept Videos
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Factors Affecting Renal Clearance: Drug Distribution and Drug Interactions
One important factor is the relationship between renal clearance and the apparent volume of distribution. Renal clearance tends to be inversely proportional to the apparent volume of distribution. Drugs with an extensive distribution volume or those...
Bioavailability Study Design: Healthy Subjects Versus Patients
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Therapeutic Drug Monitoring: Affecting Factors
Renal Drug Excretion: Glomerular Filtration
Drugs gain access to the kidney via the renal artery, which progressively branches off into afferent arterioles.